Back to search
FDAFDA · Food and drugs·Recall number D-1863-2019

Oxcarbazepine Oral Suspension, USP, 300 mg/5 mL, 250 mL per bottle, Rx Only, Distr. by: West-Ward Pharmaceuticals,Eatontown, NJ. NDC:0054-0199-59

Published September 25, 2019 · Recall initiated: September 9, 2019

Summary

FDA records drug Class II recall D-1863-2019, published September 25, 2019 and initiated September 9, 2019. Recalling firm: West-Ward Columbus Inc; Status: Terminated; Reported quantity: 32,347 bottles; Lot: Lot, expiry: Lots AA3957A, AA3958A, exp May 2020; Lot AA5164A, exp Sep 2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specificattion

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
West-Ward Columbus Inc
Distributor
Nationwide USA and Puerto Rico
Lot
Lot, expiry: Lots AA3957A, AA3958A, exp May 2020; Lot AA5164A, exp Sep 2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Oxcarbazepine Oral Suspension, USP, 300 mg/5 mL, 250 mL per bottle, Rx Only, Distr. by: West-Ward Pharmaceuticals,Eatontown, NJ. NDC:0054-0199-59 recalled?

Yes. FDA published recall D-1863-2019 on September 25, 2019. Reported hazard: Failed Impurities/Degradation Specificattion

What should I do if I have this product?

Voluntary: Firm initiated · Letter